CY1114959T1 - Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας - Google Patents

Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας

Info

Publication number: CY1114959T1
Authority: CY; Cyprus
Prior art keywords: permeability transition; mitchondrial; methods; prevent; net positive
Prior art date: 2003-02-04

Application number

CY20141100064T

Other languages

Greek (el)

English (en)

Inventor

Hazel H Szeto

Kesheng Zhao

Peter W Schiller

Original Assignee

Cornell Research Foundation, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-04

Filing date

2014-01-24

Publication date

2016-12-14

2014-01-24 Application filed by Cornell Research Foundation, Inc. filed Critical Cornell Research Foundation, Inc.

2016-12-14 Publication of CY1114959T1 publication Critical patent/CY1114959T1/el

Links

230000037050 permeability transition Effects 0.000 title abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
125000000539 amino acid group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
230000002438 mitochondrial effect Effects 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Toxicology (AREA)
Pain & Pain Management (AREA)

CY20141100064T 2003-02-04 2014-01-24 Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας CY1114959T1 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US44477703P	2003-02-04	2003-02-04
US53569004P	2004-01-08	2004-01-08
EP04707809.2A EP1599216B9 (en)	2003-02-04	2004-02-03	Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number	Publication Date
CY1114959T1 true CY1114959T1 (el)	2016-12-14

Family

ID=32853391

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CY20141100064T CY1114959T1 (el)	2003-02-04	2014-01-24	Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας
CY20151100675T CY1116575T1 (el)	2003-02-04	2015-08-03	Χρησεις αρωματικου-κατιοντικου πεπτιδιου

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20151100675T CY1116575T1 (el)	2003-02-04	2015-08-03	Χρησεις αρωματικου-κατιοντικου πεπτιδιου

Country Status (13)

Country	Link
US (8)	US7576061B2 (2)
EP (9)	EP1599216B9 (2)
JP (7)	JP4838114B2 (2)
CN (3)	CN104225574B (2)
AU (1)	AU2004209663B2 (2)
CA (1)	CA2515080C (2)
CY (2)	CY1114959T1 (2)
DK (3)	DK2656854T3 (2)
ES (3)	ES2540897T3 (2)
HU (1)	HUE027110T2 (2)
PT (2)	PT1599216E (2)
SI (1)	SI2656854T1 (2)
WO (1)	WO2004070054A2 (2)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1599216B9 (en) *	2003-02-04	2015-02-11	Cornell Research Foundation, Inc.	Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) *	2003-05-01	2015-03-31	Cornell Res Foundation Inc	Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) *	2004-01-23	2005-08-11	Cornell Research Foundation, Inc.	Methods for reducing oxidative damage
CN104788540B (zh) *	2005-09-16	2019-10-18	科内尔研究基金会	用于减少cd36表达的方法
AU2014203126B2 (en) *	2005-09-16	2016-03-10	Cornell Research Foundation, Inc.	Methods for reducing cd36 expression
EP2712620A1 (en)	2008-02-07	2014-04-02	Cornell University	Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en)	2008-02-26	2024-04-24	Cornell University	A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) *	2008-12-11	2010-06-17	Henkel Ag & Co. Kgaa	Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) *	2009-03-20	2010-12-30	Tompkins Ronald G	Methods for the prevention and treatment of burn injuries and secondary complications
WO2011019809A1 (en) *	2009-08-12	2011-02-17	Cornell University	Methods for preventing or treating metabolic syndrome
ES2964555T3 (es)	2009-08-24	2024-04-08	Stealth Biotherapeutics Inc	Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) *	2009-10-05	2011-04-14	Cornell University	Methods for the prevention or treatment of heart failure
EP3266462A1 (en) *	2009-12-31	2018-01-10	Stealth Peptides International, Inc.	Methods for performing a coronary artery bypass graft procedure
EP3090754A1 (en) *	2009-12-31	2016-11-09	Stealth Peptides International, Inc.	Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) *	2010-01-25	2011-07-28	Hazel H. Szeto	Aromatic-cationic peptides and uses of same
JP2013521231A (ja) *	2010-02-26	2013-06-10	ユニバーシティオブフロリダリサーチファウンデーションインコーポレイテッド	ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) *	2010-03-15	2018-09-19	Stealth Peptides International, Inc.	Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en)	2010-04-06	2011-10-06	Perricone Nicholas V	Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en)	2010-04-06	2011-10-06	Perricone Nicholas V	Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) *	2010-05-03	2018-03-07	Stealth Peptides International, Inc.	Aromatic-cationic peptides and uses of same
WO2014137496A1 (en) *	2013-03-08	2014-09-12	The Administrators Of The Tulane Educational Fund	Mu opioid receptor agonist analogs of the endomorphins
EP2590664B1 (en) *	2010-07-09	2019-03-27	Stealth Peptides International, Inc.	Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20160176930A1 (en)	2010-07-09	2016-06-23	The Administrators Of The Tulane Educational Fund	Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en)	2010-09-30	2012-04-05	Perricone Nicholas V	Topical Anesthetic Uses of Szeto-Schiller Peptides
EP3108975A1 (en) *	2011-03-24	2016-12-28	Cornell University	Aromatic-cationic peptides and uses of same
WO2013043580A2 (en)	2011-09-19	2013-03-28	Gencia Corporation	Modified creatine compounds
CN106913860A (zh)	2011-09-29	2017-07-04	梅约医学教育与研究基金会	芳族阳离子肽和使用它们的方法
HK1201443A1 (en) *	2011-10-17	2015-09-04	Cornell University	Aromatic-cationic peptides and uses of same
EP2788013A4 (en) *	2011-12-09	2015-08-19	Stealth Peptides Int Inc	AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN104271146A (zh)	2012-03-30	2015-01-07	康肽德生物医药技术有限公司	用于预防和治疗神经病的方法和组合物
JP2015529655A (ja) *	2012-08-02	2015-10-08	ステルスペプチドズインターナショナルインコーポレイテッド	アテローム性硬化症の処置方法
AU2013334788A1 (en) *	2012-10-22	2015-06-04	Henry Ford Health Systems	Methods for reducing risks associated with heart failure and factors associated therewith
ES2755134T3 (es)	2013-03-01	2020-04-21	Stealth Biotherapeutics Corp	Métodos para el tratamiento de enfermedad mitocondrial
US9687519B2 (en)	2013-03-01	2017-06-27	Stealth Biotherapeutics Corp	Methods and compositions for the prevention or treatment of barth syndrome
EP2989120A4 (en)	2013-04-25	2017-04-19	Carmel-Haifa University Economic Corp.	Synthetic anti-inflammatory peptides and use thereof
CA2916977A1 (en)	2013-06-26	2014-12-31	Stealth Biotherapeutics Corp	Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) *	2013-08-01	2022-08-09	Stealth Biotherapeutics Corp	Methods and compositions for preventing or treating leber's hereditary optic neuropathy
WO2015017861A1 (en)	2013-08-02	2015-02-05	Stealth Peptides International, Inc.	Methods and compositions for the prevention and treatment of friedreich's ataxia
EP3052115A4 (en) *	2013-09-30	2017-09-27	Cornell University	Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
CN106536056B (zh)	2014-06-13	2021-07-16	儿童医学中心公司	分离线粒体的产品和方法
EP3160984B1 (en)	2014-06-25	2021-04-14	Flamma S.P.A.	Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en)	2014-06-30	2016-01-07	Flamma S.P.A.	Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) *	2014-07-01	2016-01-07	Stealth Biotherapeutics Corp	Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) *	2014-09-25	2016-08-24	中山大学	Wry三肽在制备治疗阿尔茨海默症药物中的用途
EP3212194A4 (en)	2014-10-29	2018-06-20	University Of Maryland	Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) *	2015-07-23	2017-01-26	Salk Institute For Biological Studies	Prevention and treatment of aging and neurodegenerative diseases
CA3006698A1 (en) *	2015-11-30	2017-06-08	Peter Schiller	Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017124037A1 (en)	2016-01-15	2017-07-20	The Children's Medical Center Corporation	Therapeutic use of mitochondria and combined mitochondrial agents
CA3017359A1 (en)	2016-03-11	2017-09-14	Scott M. Duncan	Crystalline salt forms
WO2017180535A1 (en)	2016-04-11	2017-10-19	Carnot, Llc	Chiral peptides
KR20190088520A (ko)	2016-11-30	2019-07-26	주식회사 다이셀	촬상 장치용 렌즈 모듈 및 그의 제조 방법
US11034724B2 (en)	2017-04-05	2021-06-15	Stealth Biotherapeutics Corp.	Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
WO2019033330A1 (en)	2017-08-17	2019-02-21	Xw Laboratories, Inc.	PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES
EP3679051B1 (en)	2017-09-04	2021-12-29	XWPharma Ltd.	Preparation and use of reactive oxygen species scavenger
JP6958860B2 (ja) *	2017-11-07	2021-11-02	学校法人自治医科大学	ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en)	2018-01-26	2020-06-09	Stealth Biotherapeutics Corp.	Crystalline bis- and tris-hydrochloride salt of elamipretide
IL284006B2 (en) *	2018-12-18	2024-12-01	Stealth Biotherapeutics Corp	Mitochondria-targeting peptides
WO2020222866A1 (en) *	2019-05-02	2020-11-05	Children's Medical Center Corporation	Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en)	2019-07-30	2021-02-03	Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau	Ss-31 for the prevention and/or treatment of aneurysm
CN116390723B (zh) *	2020-09-09	2024-12-31	社会利益网络公司	用于将生物素递送至线粒体的方法和组合物
CN117881411A (zh)	2021-06-01	2024-04-12	艾迪雅生物有限责任公司	用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en)	1988-06-30	1997-02-11	Astra Ab	Dermorphin analogs having pharmacological activity
SG64368A1 (en)	1988-06-30	1999-04-27	Astra Ab	Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5670617A (en) *	1989-12-21	1997-09-23	Biogen Inc	Nucleic acid conjugates of tat-derived transport polypeptides
AU659795B2 (en) *	1990-01-17	1995-06-01	Regents Of The University Of California, The	Composition to improve survival of biological materials
US5858784A (en)	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en)	1992-06-11	1997-10-07	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
US5716644A (en)	1992-06-11	1998-02-10	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
IS4261A (is)	1994-02-21	1995-08-22	Astra Aktiebolag	Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) *	1995-06-09	2003-12-15	Hisamitsu Pharmaceutical Co	Matrix für iontophorese
US5849761A (en) *	1995-09-12	1998-12-15	Regents Of The University Of California	Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) *	1996-10-07	2004-03-18	Eli Lilly And Co., Indianapolis	Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) *	1997-03-25	1999-03-23	Administrators Of The Tulane Educational Fund	Mu-opiate receptor peptides
US5989463A (en)	1997-09-24	1999-11-23	Alkermes Controlled Therapeutics, Inc.	Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) *	1997-12-10	1999-06-17	Washington University	Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) *	1998-04-24	1999-11-04	Mitokor	Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) *	1998-08-31	2002-10-29	Pro-Neuron, Inc.	Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en)	1998-12-23	2001-06-12	Amgen Inc.	Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) *	1999-03-10	1999-05-05	Adprotech Plc	Novel compound formulations and methods of delivery
SE9900961D0 (sv)	1999-03-16	1999-03-16	Astra Ab	Novel compounds
DE60042338D1 (de) *	1999-10-04	2009-07-16	Univ New Jersey Med	TAR RNA bindende Peptide
US6759520B1 (en) *	1999-10-28	2004-07-06	The New England Medical Center Hospitals, Inc.	Chimeric analgesic peptides
US20050192215A1 (en)	2000-01-21	2005-09-01	Malabika Ghosh	Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) *	2000-07-18	2009-03-03	Cornell Research Foundation	Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) *	2000-09-12	2005-05-31	University Of Kentucky Research Foundation	Protection against ischemia and reperfusion injury
EP1339668A2 (en) *	2000-11-28	2003-09-03	Guilford Pharmaceuticals Inc.	Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6545097B2 (en) *	2000-12-12	2003-04-08	Scimed Life Systems, Inc.	Drug delivery compositions and medical devices containing block copolymer
US6656971B2 (en) *	2001-01-25	2003-12-02	Guilford Pharmaceuticals Inc.	Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) *	2001-02-02	2003-04-24	Lena Edelman	Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2002066095A2 (en) *	2001-02-16	2002-08-29	Cordis Corporation	Method of balloon catheter stent delivery system with ridges
AU2002252372A1 (en) *	2001-03-16	2002-10-03	Sts Biopolymers, Inc.	Stent with medicated multi-layer hydrid polymer coating
JPWO2002102833A1 (ja) *	2001-06-15	2004-09-30	千寿製薬株式会社	新規エンドモルフィン誘導体
EP1599216B9 (en) *	2003-02-04	2015-02-11	Cornell Research Foundation, Inc.	Methods for preventing mitochondrial permeability transition
CN101440124B (zh) *	2003-02-04	2012-07-18	科内尔研究基金会	用于防止线粒体通透性改变的方法
PL2604286T3 (pl)	2003-05-01	2015-03-31	Cornell Res Foundation Inc	Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
JP2005005762A (ja) *	2003-06-09	2005-01-06	Fujitsu Ltd	送信電力制御方法及び装置
WO2005032481A2 (en)	2003-09-30	2005-04-14	Scios Inc.	Quinazoline derivatives as medicaments
CA3024434A1 (en) *	2004-01-23	2005-08-11	Cornell Research Foundation, Inc.	Methods for reducing oxidative damage
CN104788540B (zh)	2005-09-16	2019-10-18	科内尔研究基金会	用于减少cd36表达的方法

2004
- 2004-02-03 EP EP04707809.2A patent/EP1599216B9/en not_active Expired - Lifetime
- 2004-02-03 CA CA2515080A patent/CA2515080C/en not_active Expired - Lifetime
- 2004-02-03 EP EP11009660.9A patent/EP2491943B1/en not_active Expired - Lifetime
- 2004-02-03 EP EP17192437.6A patent/EP3305313A1/en not_active Withdrawn
- 2004-02-03 CN CN201410412683.1A patent/CN104225574B/zh not_active Expired - Lifetime
- 2004-02-03 AU AU2004209663A patent/AU2004209663B2/en not_active Expired
- 2004-02-03 EP EP14186875.2A patent/EP2865385B1/en not_active Expired - Lifetime
- 2004-02-03 ES ES13178043.9T patent/ES2540897T3/es not_active Expired - Lifetime
- 2004-02-03 CN CN201210177633.0A patent/CN102784383B/zh not_active Expired - Lifetime
- 2004-02-03 EP EP16192437.8A patent/EP3144009A1/en not_active Withdrawn
- 2004-02-03 DK DK13178043.9T patent/DK2656854T3/en active
- 2004-02-03 US US10/771,232 patent/US7576061B2/en not_active Expired - Lifetime
- 2004-02-03 HU HUE13178043A patent/HUE027110T2/en unknown
- 2004-02-03 PT PT47078092T patent/PT1599216E/pt unknown
- 2004-02-03 EP EP20210900.5A patent/EP3842055A1/en active Pending
- 2004-02-03 DK DK14186875.2T patent/DK2865385T3/en active
- 2004-02-03 EP EP18199147.2A patent/EP3479838A1/en not_active Withdrawn
- 2004-02-03 PT PT131780439T patent/PT2656854E/pt unknown
- 2004-02-03 ES ES04707809T patent/ES2436011T3/es not_active Expired - Lifetime
- 2004-02-03 ES ES14186875.2T patent/ES2605504T3/es not_active Expired - Lifetime
- 2004-02-03 JP JP2006503317A patent/JP4838114B2/ja not_active Expired - Lifetime
- 2004-02-03 CN CN2012100218642A patent/CN102617706A/zh active Pending
- 2004-02-03 EP EP20130178043 patent/EP2656854B1/en not_active Expired - Lifetime
- 2004-02-03 WO PCT/US2004/003193 patent/WO2004070054A2/en not_active Ceased
- 2004-02-03 EP EP19207802.0A patent/EP3659618A1/en not_active Withdrawn
- 2004-02-03 SI SI200432258T patent/SI2656854T1/sl unknown
- 2004-02-03 DK DK04707809.2T patent/DK1599216T3/da active
2006
- 2006-06-30 US US11/427,804 patent/US7718620B2/en active Active
2010
- 2010-04-02 US US12/753,403 patent/US20100190718A1/en not_active Abandoned
- 2010-10-28 JP JP2010241738A patent/JP5775285B2/ja not_active Expired - Lifetime
2011
- 2011-09-28 US US13/247,648 patent/US8404646B2/en not_active Expired - Fee Related
2013
- 2013-02-27 US US13/778,994 patent/US8957030B2/en not_active Expired - Lifetime
- 2013-09-03 JP JP2013182343A patent/JP5837542B2/ja not_active Expired - Lifetime
2014
- 2014-01-24 CY CY20141100064T patent/CY1114959T1/el unknown
- 2014-10-01 JP JP2014202889A patent/JP6126059B2/ja not_active Expired - Lifetime
2015
- 2015-01-13 US US14/595,946 patent/US20150359838A1/en not_active Abandoned
- 2015-07-06 JP JP2015135207A patent/JP6166312B2/ja not_active Expired - Lifetime
- 2015-08-03 CY CY20151100675T patent/CY1116575T1/el unknown
2017
- 2017-02-15 JP JP2017025764A patent/JP2017095519A/ja active Pending
2019
- 2019-01-08 JP JP2019001256A patent/JP2019089773A/ja active Pending
- 2019-09-12 US US16/569,573 patent/US20200038472A1/en not_active Abandoned
2022
- 2022-02-10 US US17/668,744 patent/US20230293624A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2865385T3 (en)	2016-12-19
JP6126059B2 (ja)	2017-05-10
EP2865385A1 (en)	2015-04-29
AU2004209663B2 (en)	2009-01-15
US20130244957A1 (en)	2013-09-19
JP5775285B2 (ja)	2015-09-09
EP3144009A1 (en)	2017-03-22
WO2004070054A2 (en)	2004-08-19
EP3842055A1 (en)	2021-06-30
JP6166312B2 (ja)	2017-07-19
JP2011026346A (ja)	2011-02-10
US7718620B2 (en)	2010-05-18
US20040248808A1 (en)	2004-12-09
US20150359838A1 (en)	2015-12-17
PT2656854E (pt)	2015-09-03
JP2015180693A (ja)	2015-10-15
EP2491943B1 (en)	2018-10-10
CA2515080C (en)	2012-04-10
WO2004070054A3 (en)	2005-04-14
EP2491943A2 (en)	2012-08-29
HK1131995A1 (en)	2010-02-12
DK1599216T3 (da)	2013-12-09
ES2436011T3 (es)	2013-12-26
EP1599216A4 (en)	2009-11-11
ES2605504T3 (es)	2017-03-14
HK1204999A1 (en)	2015-12-11
HK1190930A1 (en)	2014-07-18
US20070027087A1 (en)	2007-02-01
HK1178794A1 (en)	2013-09-19
ES2540897T3 (es)	2015-07-14
CN102617706A (zh)	2012-08-01
US20100190718A1 (en)	2010-07-29
PT1599216E (pt)	2013-12-17
AU2004209663A1 (en)	2004-08-19
JP2013249313A (ja)	2013-12-12
US8404646B2 (en)	2013-03-26
JP4838114B2 (ja)	2011-12-14
SI2656854T1 (sl)	2015-09-30
EP2656854A1 (en)	2013-10-30
HK1209652A1 (en)	2016-04-08
US8957030B2 (en)	2015-02-17
CY1116575T1 (el)	2017-03-15
EP2491943A3 (en)	2013-01-23
DK2656854T3 (en)	2015-07-06
CN102784383A (zh)	2012-11-21
HK1090571A1 (en)	2006-12-29
CA2515080A1 (en)	2004-08-19
HUE027110T2 (en)	2016-08-29
US20200038472A1 (en)	2020-02-06
AU2004209663A2 (en)	2004-08-19
EP1599216B1 (en)	2013-11-06
JP2019089773A (ja)	2019-06-13
US20230293624A1 (en)	2023-09-21
EP2656854B1 (en)	2015-05-20
CN102784383B (zh)	2014-09-17
JP2006516652A (ja)	2006-07-06
JP2015007127A (ja)	2015-01-15
CN104225574A (zh)	2014-12-24
EP1599216A2 (en)	2005-11-30
EP3659618A1 (en)	2020-06-03
EP3479838A1 (en)	2019-05-08
EP1599216B9 (en)	2015-02-11
EP2865385B1 (en)	2016-11-16
US20120021970A1 (en)	2012-01-26
EP3305313A1 (en)	2018-04-11
JP2017095519A (ja)	2017-06-01
CN104225574B (zh)	2017-01-11
US7576061B2 (en)	2009-08-18
JP5837542B2 (ja)	2015-12-24

Publication	Publication Date	Title
CY1114959T1 (el)	2016-12-14	Μεθοδοι προληψης της μεταπτωσης μιτοχονδριακης διαπερατοτητας
CY1115305T1 (el)	2017-01-04	Μεθοδοι για την προληψη ή τη θεραπεια της αντιστασης στην ινσουλινη
CY1109439T1 (el)	2014-08-13	Αναλογα γλυκοπρωτεϊνικων ορμονων δισουλφιδικης σταυρωτης συνδεσης, η παρασκευη και η χρηση τους
CY1113537T1 (el)	2016-06-22	Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα
CY1110177T1 (el)	2015-01-14	Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1110609T1 (el)	2015-04-29	Μεθοδος για την παρασκευη μιας διασφαλισμενης εναντια σε καταχρηση μορφης χορηγησης
DE69841105D1 (de)	2009-10-08	Chemokine peptide, varianten, derivate und analoge. ihre verwendung in methode für die hemmung oder erhöhung von einer entzündungsreaktion
CY1117704T1 (el)	2017-05-17	Μειγματα πολυπεπτιδιων, συνθεσεις που περιεχουν και διεργασιες για την παρασκευη και τη χρηση τους
CY1109219T1 (el)	2014-07-02	Ινδολο, αζαινδολο και σχετικα ετεροκυκλικα αμιδοπιπεραζινο παραγωγα
DE60319552D1 (de)	2008-04-17	Fluorpolymerzusammensetzungen
DE60325968D1 (de)	2009-03-12	Prodrugs von exzitatorischen aminosäuren
CY1112704T1 (el)	2016-02-10	Ανοσοδιεγερτικα ολιγονουκλεοτιδια ακολουθιας και μεθοδοι χρησης τους
NO20020705L (no)	2002-08-14	Generell strömbegrensende höyspenningssikring
ES2058809T3 (es)	1994-11-01	Derivados heterociclicos.
CY1108570T1 (el)	2014-04-09	Gd3-μιμητικα πεπτιδια
DK1751695T3 (da)	2008-09-08	Identificering af billedegenskaber
BR0109428A (pt)	2002-12-10	Formas de onda de fonte para exploração eletrosìsmica
RU2009147217A (ru)	2011-06-27	Новые противоопухолевые соединения
EA200000950A1 (ru)	2001-02-26	Ингерентно свето- и термостабилизированные полиамиды с улучшенной устойчивостью к мокрым обработкам
EP1548107A4 (en)	2006-07-26	CHROMOPROTEIN AND FLUORO PROTEINS
ITRM940134A1 (it)	1994-09-17	Circuito per combinare insieme gruppi di sequenze di cifre per formare codici di identificazione telefonici e relativo procedimento
KR910018404A (ko)	1991-11-30	혈소판-응집 억제제
CY1109946T1 (el)	2014-09-10	Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
CY1105235T1 (el)	2010-03-03	Συνθεσεις λασοφοξιφενης
ES2164297T3 (es)	2002-02-16	Preparacion de (poli)peptidos purificados.